Medroxyprogesterone, a synthetic progestin used in hormonal therapies such as contraception and the treatment of menstrual disorders, was developed in the mid-20th century and later approved for widespread medical use. Its history is characterized by its effectiveness in regulating ovulation and managing conditions like endometriosis and abnormal uterine bleeding, while also raising concerns about potential side effects with long-term use. Medroxyprogesterone is commonly used in various formulations, including injectable contraceptives and oral therapies, and has become a key component in reproductive health management. Its development included extensive clinical evaluation and post-marketing surveillance programs to monitor safety and optimize patient outcomes.
BRAND NAMES
Depo-Provera – a widely used injectable contraceptive given every 3 months
Provera – oral tablets used for menstrual disorders and hormone therapy
Depo-SubQ Provera 104 – a lower-dose injectable form administered under the skin.
MECHANISM OF ACTION
Medroxyprogesterone acts as a synthetic form of progesterone by binding to progesterone receptors in reproductive tissues and altering hormonal signaling. It suppresses ovulation primarily by inhibiting the release of gonadotropins from the pituitary gland, especially luteinizing hormone, thereby preventing the mid-cycle surge required for ovulation.
PHARMACOKINETICS
Absorption
Medroxyprogesterone is well absorbed after both oral and parenteral administration. When taken orally, it is rapidly absorbed from the gastrointestinal tract, though it undergoes significant first-pass metabolism in the liver, which affects its bioavailability.
Distribution
Medroxyprogesterone has an approximate apparent volume of distribution of 20–30 L (for oral formulations), indicating moderate to extensive distribution into body tissues.
Metabolism
Medroxyprogesterone is extensively metabolized in the liver, primarily via hydroxylation and conjugation reactions. The metabolism is largely mediated by hepatic enzymes, particularly the Cytochrome P450 3A4 system.
Elimination
Medroxyprogesterone is eliminated primarily through hepatic metabolism, with its metabolites excreted via both urine and feces. After metabolism in the liver, the drug is converted into inactive conjugated metabolites (such as glucuronides and sulfates), which are then cleared from the body.
PHARMACODYNAMICS
Medroxyprogesterone exerts its effects by acting as a progestin (progesterone receptor agonist), mimicking the natural hormone progesterone in target tissues. It binds to intracellular progesterone receptors and modulates gene expression, leading to changes in the reproductive system.
ADMINISTRATION
Medroxyprogesterone is administered through multiple routes depending on the clinical indication and formulation. It is available as oral tablets (e.g., Provera) for daily use in conditions such as menstrual disorders and hormone therapy.
DOSAGE AND STRENGTH
Medroxyprogesterone is available in multiple dosage forms and strengths depending on its clinical use. Oral tablets are commonly available in strengths of 2.5 mg, 5 mg, and 10 mg, and are typically used for menstrual disorders and hormone therapy.
DRUG INTERACTIONS
Medroxyprogesterone has clinically important drug interactions mainly due to its hepatic metabolism, especially via the Cytochrome P450 3A4 system. Drugs that induce CYP3A4 such as rifampicin, carbamazepine, phenytoin, and some antiretrovirals can increase the metabolism of medroxyprogesterone, leading to reduced plasma levels and decreased contraceptive or therapeutic efficacy.
FOOD INTERACTIONS
Medroxyprogesterone has no significant or clinically important direct food interactions. Its absorption and overall effectiveness are generally not affected by food intake, so oral formulations can be taken with or without meals.
CONTRAINDICATIONS
Medroxyprogesterone is contraindicated in several conditions where progestin use may worsen the disease or pose significant risk. It should not be used in patients with known or suspected pregnancy, as it may affect fetal development and is not intended for use during pregnancy.
SIDE EFFECTS
Menstrual irregularities (spotting, breakthrough bleeding, amenorrhea)
Weight gain
Bloating and fluid retention
Headache
Dizziness
Mood changes (depression, irritability)
Decreased libido
Breast tenderness
OVER DOSAGE
Overdose of Medroxyprogesterone is uncommon and is generally not associated with life-threatening toxicity. When it does occur, the symptoms are usually an exaggeration of its normal pharmacological effects, such as nausea, vomiting, dizziness, drowsiness, breakthrough bleeding, breast tenderness, and mood changes.
TOXICITY
Toxicity from Medroxyprogesterone is generally low, and severe toxic reactions are rare even at high doses. When toxicity occurs, it is usually related to excessive progestogenic activity rather than direct organ damage. Clinical features may include pronounced menstrual disturbances (amenorrhea or irregular bleeding), marked weight gain, fluid retention, mood disturbances (including depression), fatigue, and dizziness.
